BioSpace News Archive

Mereo BioPharma Group plc, a clinical stage biopharmaceutical company focused on oncology and rare diseases, announced it will host a virtual R&D day on Tuesday, November 24, to review the Company’s key pipeline programs including etigilimab for solid tumors and alvelestat for alpha-1 antitrypsin deficiency and COVID-19 respiratory disease.

Skin Reaction or “Take,” a Validated Biomarker of Functional T cell Immunity, Elicited in All Eight TNX-1800 Vaccinated Animals

Clearside Biomedical, Inc., a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced that two presentations of Clearside preclinical and clinical data were given at the virtual American Academy Ophthalmology 2020 Annual Meeting.

Study met primary endpoint showing statistically significant improvement in rate of prevention of Grade 4 neutropenia in Cycle 1, p=0.0015

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium”) today announced that it will be participating in the Alliance Global Partners’ Virtual Healthcare Symposium being held on Thursday, November 19, 2020 . During the event, Actinium’s Chief Medical Officer Mark Berger will participate in a panel discussing emerging tre

INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced that it has received clearance from the U.S. Food & Drug Administration (FDA) to proceed with the Phase 2 segment of its planned Pha

Q-State Biosciences (“Q-State”), a precision therapeutics company developing treatments for diseases associated with electrically excitable cells, announced today multiple additions and appointments to its board of directors supporting the company’s strategic advancement. Steven Hyman, MD, and Matthew Might, PhD, join the Q-State board as independent directors, and current board member Mark Evenstad is appointed Chair f

Ribon Therapeutics to Present at the Piper Sandler 32 nd Annual Virtual Healthcare Conference

The proof-of-concept study demonstrated efficacy, safety, and tolerability of Tanfanercept for the treatment of moderate-to-severe dry eye disease (DED) in China

Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the virtual Piper Sandler Healthcare Conference, being held December 1-3, 2020. The company will conduct institutional investor meetings on December 2, 2020. The pre-recorded fireside